It has now become known that the European Medicines Agency (EMA) is currently reviewing the results of the RECOVERY study on the dexamethasone arm. “Part of the study examined the effectiveness of adding dexamethasone to the usual treatment of adults who were on artificial respiration, who were given additional oxygen (for example through a mask) or who did not need oxygen therapy. With artificial respiration, air is pressed through a hose using a machine, which is inserted into the patient’s airways, ”explains the Federal Institute for Drugs and Medical Devices (BfArM). Because the results of the study are apparently promising, the evaluation by the EMA should now enable an opinion on the results of the RECOVERY study and in particular on the possible use of dexamethasone for the treatment of adults with COVID-19.
The review of dexamethasone is said to have been initiated following a preliminary discussion with the EMA pandemic task force COVID-19 (COVID-ETF) at the request of the EMA’s senior director (pursuant to Article 5 (3) of Regulation 726/2004).